tACS for Aphasia After Stroke
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new approach to help stroke survivors improve language skills. It uses transcranial alternating current stimulation (tACS), which sends mild electrical currents to the brain, combined with speech therapy focused on short-term memory. The trial compares two groups: one receives active HD-tACS treatment, and the other receives a sham (placebo-like) treatment. It is ideal for those who have experienced a stroke affecting the left side of the brain and are facing language problems (aphasia). Participants should be fluent in English and have had their stroke at least one month ago. As an unphased trial, this study offers a unique opportunity to explore innovative treatments that could enhance recovery and improve the quality of life for stroke survivors.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that HD-tACS is safe for language recovery after stroke?
Research has shown that transcranial alternating current stimulation (tACS) is generally safe. Studies have found that tACS can aid stroke recovery without causing serious side effects. Participants often feel mild sensations, like tingling, during treatment. This suggests that tACS is safe for most people, with only minor discomfort reported.
Researchers are studying the treatment's potential to help stroke patients regain language skills. So far, studies have not identified any major safety concerns, making it a promising option for those considering joining a trial.12345Why are researchers excited about this trial?
Most treatments for aphasia after a stroke involve speech therapy and medications to improve blood flow to the brain. However, high-definition transcranial alternating current stimulation (HD-tACS) is unique because it directly targets brain activity with electrical stimulation, potentially enhancing brain plasticity and recovery. Researchers are excited about HD-tACS because it offers a non-invasive way to boost the effects of traditional speech therapy by applying mild electrical currents to the brain, which could accelerate recovery. Additionally, pairing HD-tACS with short-term memory-focused speech therapy might provide a more comprehensive approach, potentially improving both memory and language skills simultaneously.
What evidence suggests that HD-tACS is effective for language recovery after stroke?
Research has shown that transcranial alternating current stimulation (tACS) can aid in language recovery after a stroke. One study found that tACS helped stroke patients improve their overall recovery. Another study indicated that tACS might enhance speech for people with nonfluent aphasia, a condition where speaking is challenging. In this trial, participants will receive either HD-tACS or Sham HD-tACS, both paired with short-term memory-focused speech therapy. These findings suggest that HD-tACS could help restore brain functions related to language. While more research is needed, early results are promising for those with language difficulties after a stroke.12367
Are You a Good Fit for This Trial?
This trial is for English-speaking adults over 18 who have had a stroke affecting the left side of their brain, leading to aphasia. They must be at least one month post-stroke. People with severe sensory impairments, untreated psychiatric diseases, unstable medical conditions, pacemakers or cardiac stimulators, seizure disorders, dyslexia or learning disabilities cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive high-definition tACS combined with short-term memory focused speech therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- HD-tACS
- Sham HD-tACS
HD-tACS is already approved in United States, European Union for the following indications:
- Research use for conditions such as aphasia after stroke
- Fibromyalgia (research use)
- Research use for neurological conditions
- Memory enhancement in older adults (research use)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical College of Wisconsin
Lead Sponsor